Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study

20260 citationsJournal Articlehybrid Open Access

Authors

Franco Scaldaferri · Università Cattolica del Sacro Cuore

Federica Di Vincenzo · Università Cattolica del Sacro Cuore

M Aloi · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

M. Ascolani · Ca' Foncello Hospital

Paola Balestrieri · Università Campus Bio-Medico

Lorenzo Bertani · École nationale des ponts et chaussées

Cristina Bezzio

Abstract

In a large, refractory, real-world CD population, RZB induced rapid and sustained favorable clinical, endoscopic, and radiologic outcomes. Importantly, one-year effectiveness was similar in patients with 2, and ≥3 previous failures, supporting RZB as a valuable option for a refractory population.

Topics & Keywords

Inflammatory Bowel Disease Autoimmune and Inflammatory Disorders Biosimilars and Bioanalytical Methods

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The American Journal of Gastroenterology

DOI: 10.14309/ajg.0000000000003969

Field-Weighted Citation Impact: 0.00